- Trial phase
- Phase 1 completed; Phase 2a planned
- Time to market
- At least 4-6 years away, if successful. The AscenSION CF Phase 2a trial has not yet started (expected Q1 2027). Even in a best case, Phase 2a readout would be 12-18 months away, followed by larger Phase 3 trials and FDA review.
- Why 4/10
- The next hard catalyst is the start of the AscenSION CF Phase 2a trial for SION-451 + SION-2222, expected in Q1 2027 (about 4 months away). However, a trial initiation is not a binary readout; the actual Phase 2a topline data is likely 12-18 months away. SION-451 is now the company's lead asset after SION-719 failed, but it remains early-stage with no proof-of-concept data in patients yet.
Watch for the initiation of the AscenSION CF Phase 2a trial for SION-451 + SION-2222 in Q1 2027. This trial start will signal the company's ability to execute after the workforce reduction, but the real binary event will be the Phase 2a topline efficacy readout, which is likely 12-18 months away. The stock's extreme post-failure valuation ($3.57, down 92% from the high) and $249M cash position create an asymmetric risk/reward, but SION-451 has no clinical proof-of-concept yet in patients.
Price Chart
Executive Summary
SION-451 is an NBD1 stabilizer for cystic fibrosis being developed by Sionna Therapeutics (NASDAQ: SION). After the company's lead program SION-719 failed a Phase 2a trial in August 2026 (crushing the stock by ~92%), SION-451 became the company's primary focus. It is being advanced as a dual combination with SION-2222 into a Phase 2a proof-of-concept trial (AscenSION CF) expected to start in Q1 2027. The company has a strong cash position of ~$249 million and a runway into 2029, but SION-451 has not yet demonstrated efficacy in CF patients, and the stock trades near its all-time low of $3.19 after the devastating trial failure of its predecessor program.
How It Works
SION-451 is an NBD1 (nucleotide binding domain 1) stabilizer, a type of small molecule designed to fix a defective protein called CFTR that causes cystic fibrosis. In people with CF, the CFTR protein misfolds and cannot reach the cell surface to regulate salt and water. SION-451 aims to stabilize the NBD1 region of CFTR, helping the protein fold correctly and function more normally. It is being developed as a dual combination with another drug (SION-2222) that targets a different part of the CFTR protein, potentially offering a treatment that could work for a broad CF population without needing to be added to existing therapies like Vertex's Trikafta.
Trial Status
SION-451 completed Phase 1 healthy-volunteer trials with positive safety and pharmacokinetic data announced in June 2025. A Phase 1 dual-combination trial (SION-451 paired with SION-2222 or SION-109) was dosed starting August 2025, with topline data reported in August 2026. On September 14, 2026, Sionna announced plans to advance the SION-451 + SION-2222 combination into a Phase 2a proof-of-concept trial called AscenSION CF. As of the Q3 2026 earnings report (November 10, 2026), the AscenSION CF trial is expected to initiate in the first quarter of 2027.
The Two-Sided Case
Upcoming Catalysts
- Initiation of AscenSION CF Phase 2a proof-of-concept trial for SION-451 + SION-2222, expected Q1 2027
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Sionna Therapeutics, Inc. PRESS-RELEASE SION ·Originating report